Thomas Gad Sells 10,810 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Stock

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) insider Thomas Gad sold 10,810 shares of Y-mAbs Therapeutics stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $5.23, for a total value of $56,536.30. Following the transaction, the insider now owns 202,721 shares of the company’s stock, valued at $1,060,230.83. This represents a 5.06 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Y-mAbs Therapeutics Price Performance

Shares of YMAB stock opened at $4.73 on Friday. The firm has a market capitalization of $213.88 million, a P/E ratio of -8.76 and a beta of 0.65. Y-mAbs Therapeutics, Inc. has a 12 month low of $4.25 and a 12 month high of $17.78. The company’s fifty day moving average price is $6.11 and its two-hundred day moving average price is $10.28.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its quarterly earnings data on Tuesday, March 4th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.02). Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. The business had revenue of $26.50 million for the quarter, compared to analyst estimates of $26.70 million. During the same quarter last year, the company earned ($0.02) EPS. On average, sell-side analysts anticipate that Y-mAbs Therapeutics, Inc. will post -0.65 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of YMAB. Principal Financial Group Inc. boosted its holdings in shares of Y-mAbs Therapeutics by 9.4% in the fourth quarter. Principal Financial Group Inc. now owns 22,197 shares of the company’s stock valued at $174,000 after acquiring an additional 1,903 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Y-mAbs Therapeutics by 12.6% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,818 shares of the company’s stock worth $179,000 after buying an additional 2,545 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Y-mAbs Therapeutics by 10.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 30,335 shares of the company’s stock valued at $399,000 after acquiring an additional 2,854 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Y-mAbs Therapeutics in the 3rd quarter valued at approximately $44,000. Finally, SG Americas Securities LLC lifted its position in shares of Y-mAbs Therapeutics by 30.7% in the 4th quarter. SG Americas Securities LLC now owns 17,729 shares of the company’s stock valued at $139,000 after acquiring an additional 4,163 shares in the last quarter. Institutional investors own 70.85% of the company’s stock.

Analysts Set New Price Targets

YMAB has been the subject of several research reports. Wedbush restated an “outperform” rating and set a $23.00 price objective on shares of Y-mAbs Therapeutics in a research report on Monday, March 3rd. HC Wainwright reiterated a “buy” rating and issued a $22.00 price target on shares of Y-mAbs Therapeutics in a report on Monday, January 13th. Brookline Capital Management assumed coverage on Y-mAbs Therapeutics in a report on Thursday, December 5th. They issued a “buy” rating and a $17.00 price target for the company. Bank of America cut their price target on Y-mAbs Therapeutics from $14.00 to $12.00 and set a “neutral” rating for the company in a report on Wednesday, March 5th. Finally, Morgan Stanley cut their price target on Y-mAbs Therapeutics from $11.00 to $7.00 and set an “underweight” rating for the company in a report on Wednesday, March 5th. One research analyst has rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $19.30.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.